Heartflow (NASDAQ:HTFL) Price Target Lowered to $35.00 at JPMorgan Chase & Co.

Heartflow (NASDAQ:HTFL) had its target price cut by JPMorgan Chase & Co. from $40.00 to $35.00 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company cut their price objective on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Canaccord Genuity Group increased their target price on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.67.

Heartflow Trading Up 1.6%

Shares of HTFL stock opened at $25.89 on Thursday. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22. The stock has a market capitalization of $2.20 billion and a P/E ratio of -14.30. The firm’s 50 day moving average is $27.01 and its 200 day moving average is $30.45.

Insider Buying and Selling at Heartflow

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the transaction, the insider directly owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John C.M. Farquhar sold 12,837 shares of Heartflow stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total transaction of $290,886.42. Following the transaction, the chief executive officer owned 581,450 shares in the company, valued at $13,175,657. This represents a 2.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,117,674 shares of company stock valued at $59,052,646 in the last ninety days.

Institutional Trading of Heartflow

Several hedge funds have recently bought and sold shares of HTFL. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the fourth quarter worth about $27,000. TFC Financial Management Inc. purchased a new position in shares of Heartflow during the 3rd quarter valued at about $40,000. Russell Investments Group Ltd. bought a new position in shares of Heartflow during the 4th quarter valued at approximately $45,000. Legal & General Group Plc purchased a new stake in Heartflow in the 3rd quarter worth approximately $59,000. Finally, Strs Ohio bought a new stake in Heartflow during the 4th quarter worth approximately $99,000.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong growth — HeartFlow reported Q4 revenue of $49.13M (vs. $46.58M consensus) and year-over-year revenue growth of ~40.5%, a key driver for optimism about adoption and recurring revenue. Earnings Release / Transcript
• Positive Sentiment: Canaccord raised its price target to $43 and maintained a Buy rating — this is a constructive analyst signal that implies sizeable upside from current levels and likely supported the intraday gain. Canaccord Raise (Benzinga)
• Positive Sentiment: Longer-term growth narrative—coverage noting HeartFlow as an AI/advanced-imaging beneficiary may be underpinning investor interest in the stock’s growth prospects. AI Beneficiary Article (MSN)
• Neutral Sentiment: Analyst & research coverage continues — independent write-ups and the full earnings call transcript provide more detail for investors to reassess forecasts and growth assumptions. Seeking Alpha Analysis Earnings Call Transcript
• Negative Sentiment: EPS miss and analyst target trims — Q4 EPS was ($0.29) vs. consensus ($0.16), a notable downside vs. expectations that tempers the revenue beat. Separately, JPMorgan and Wells Fargo trimmed price targets (both to $35) though kept overweight ratings, reducing some upside implied by prior targets. Earnings Details (MarketBeat) JPMorgan / Wells Fargo Notes (Benzinga)

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.